Cargando…

Repurposing drugs to treat cardiovascular disease in the era of precision medicine

Drug repurposing is the use of a given therapeutic agent for indications other than that for which it was originally designed or intended. The concept is appealing because of potentially lower development costs and shorter timelines than are needed to produce a new drug. To date, drug repurposing fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdelsayed, Mena, Kort, Eric J., Jovinge, Stefan, Mercola, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9125554/
https://www.ncbi.nlm.nih.gov/pubmed/35606425
http://dx.doi.org/10.1038/s41569-022-00717-6
_version_ 1784711961688145920
author Abdelsayed, Mena
Kort, Eric J.
Jovinge, Stefan
Mercola, Mark
author_facet Abdelsayed, Mena
Kort, Eric J.
Jovinge, Stefan
Mercola, Mark
author_sort Abdelsayed, Mena
collection PubMed
description Drug repurposing is the use of a given therapeutic agent for indications other than that for which it was originally designed or intended. The concept is appealing because of potentially lower development costs and shorter timelines than are needed to produce a new drug. To date, drug repurposing for cardiovascular indications has been opportunistic and driven by knowledge of disease mechanisms or serendipitous observation rather than by systematic endeavours to match an existing drug to a new indication. Innovations in two areas of personalized medicine — computational approaches to associate drug effects with disease signatures and predictive model systems to screen drugs for disease-modifying activities — support efforts that together create an efficient pipeline to systematically repurpose drugs to treat cardiovascular disease. Furthermore, new experimental strategies that guide the medicinal chemistry re-engineering of drugs could improve repurposing efforts by tailoring a medicine to its new indication. In this Review, we summarize the historical approach to repurposing and discuss the technological advances that have created a new landscape of opportunities.
format Online
Article
Text
id pubmed-9125554
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-91255542022-05-23 Repurposing drugs to treat cardiovascular disease in the era of precision medicine Abdelsayed, Mena Kort, Eric J. Jovinge, Stefan Mercola, Mark Nat Rev Cardiol Review Article Drug repurposing is the use of a given therapeutic agent for indications other than that for which it was originally designed or intended. The concept is appealing because of potentially lower development costs and shorter timelines than are needed to produce a new drug. To date, drug repurposing for cardiovascular indications has been opportunistic and driven by knowledge of disease mechanisms or serendipitous observation rather than by systematic endeavours to match an existing drug to a new indication. Innovations in two areas of personalized medicine — computational approaches to associate drug effects with disease signatures and predictive model systems to screen drugs for disease-modifying activities — support efforts that together create an efficient pipeline to systematically repurpose drugs to treat cardiovascular disease. Furthermore, new experimental strategies that guide the medicinal chemistry re-engineering of drugs could improve repurposing efforts by tailoring a medicine to its new indication. In this Review, we summarize the historical approach to repurposing and discuss the technological advances that have created a new landscape of opportunities. Nature Publishing Group UK 2022-05-23 2022 /pmc/articles/PMC9125554/ /pubmed/35606425 http://dx.doi.org/10.1038/s41569-022-00717-6 Text en © Springer Nature Limited 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Review Article
Abdelsayed, Mena
Kort, Eric J.
Jovinge, Stefan
Mercola, Mark
Repurposing drugs to treat cardiovascular disease in the era of precision medicine
title Repurposing drugs to treat cardiovascular disease in the era of precision medicine
title_full Repurposing drugs to treat cardiovascular disease in the era of precision medicine
title_fullStr Repurposing drugs to treat cardiovascular disease in the era of precision medicine
title_full_unstemmed Repurposing drugs to treat cardiovascular disease in the era of precision medicine
title_short Repurposing drugs to treat cardiovascular disease in the era of precision medicine
title_sort repurposing drugs to treat cardiovascular disease in the era of precision medicine
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9125554/
https://www.ncbi.nlm.nih.gov/pubmed/35606425
http://dx.doi.org/10.1038/s41569-022-00717-6
work_keys_str_mv AT abdelsayedmena repurposingdrugstotreatcardiovasculardiseaseintheeraofprecisionmedicine
AT kortericj repurposingdrugstotreatcardiovasculardiseaseintheeraofprecisionmedicine
AT jovingestefan repurposingdrugstotreatcardiovasculardiseaseintheeraofprecisionmedicine
AT mercolamark repurposingdrugstotreatcardiovasculardiseaseintheeraofprecisionmedicine